- NEW DAY Study: A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
- Pavilion Study: A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy
- Cool-3 Study: Long Term Evaluation of Efficacy of Cooling Anesthesia for Local Anesthesia During Intravitreal Injection
- Catalina (NGM621-GA-201): A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Candela: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
- Canberra: A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy-ORAL THERAPY
- Pagoda Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients With Diabetic Macular Edema. Sponsor: Genentech/RocheNorse Two Study: A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration. Sponsor: Outlook TherapeuticsSalutartis: A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age-related Macular Degeneration. Sponsor: Salutaris Medical Devices
- Gallego Study: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech/Roche
- Altissimo: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study). Sponsor: Graybug Vision
- GTSCOPE: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration. Sponsor: Gyroscope Therapeutics
- Ionis: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD). Sponsor: Ionis Pharmaceuticals
- Kingfisher Study: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema. Sponsor: Novartis
- Lucerne Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration. Sponsor: Genentech/Roche
- Archway Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Genentech/Roche
- Rhine Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema. Sponsor: Genentech/Roche
- Panda 1: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration. Sponsor: Chengdu Kanghong
- Topaz Study: Phase 3, multicenter, randomized, masked, controlled, parallel group study of suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO vs. IVT anti-VEGF agent used alone. Sponsor: Clearside Biomedical
- Cedar Study: A phase 3, multicenter, study of abicipar pegol in patients with neovascular age-related macular degeneration. Sponsor: Allergan
- Panorama: A phase 3, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy. Sponsor: Regeneron
- Boulevard: A multiple center, multiple dose, randomized, active comparator controlled, double-masked, parallel group, 24-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravtireally in patients with diabetic macular edema. Sponsor: Genentech/Roche
- Chroma: A phase 3, multicenter, randomized double-masked sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration. Sponsor: Genentech/Roche
- Onyx: A randomized, double-masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration. Sponsor: RegeneronPhase 2, randomized, double-masked, vehicle-controlled, proof of concept study for topically delivered LHA510 as a maintenance therapy in wet AMD. Sponsor: Alcon
- Capella: a phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration. Sponsor: Regeneron.
- Protocol OPH1006: An 18 month phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer). Sponsor: Ophthotech.
- Protocol OPH1005: Phase 2A open label safety study of Fovista (anti-PDGF BB) regimen administered in combination with anti-VEGF therapy to study sub-retinal fibrosis in neovascular AMD. Sponsor: Ophthotech
- Protocol OPH1004: A phase 3 safety and efficacy study of Fovista intravitreous administration in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy. Sponsor: Ophthotech
- ORBIT study: Phase 4 study of intravtireal Jetrea for vitreomacular adhesion. Sponsor: Thrombogenics
- Diabetic Retinopathy Clinical Research Network (DRCR.net): A collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. Protocols R, V, U, and AC. Sponsor: NEI.
